Immunogenicity and induction of immunological memory of the heptavalent pneumococcal conjugate vaccine in preterm UK infants

Data on the immunogenicity and memory induction of pneumococcal conjugate vaccines in very preterm infants is limited. We vaccinated 69 full term and 68 preterm infants (median gestational age (GA) 30 weeks) with a 7-valent pneumococcal conjugate vaccine (PCV7) at 2/3/4 months of age, followed by a...

Full description

Bibliographic Details
Main Authors: Ruggeberg, J, Collins, C, Clarke, P, Johnson, N, Sinha, R, Everest, N, Chang, J, Stanford, E, Balmer, P, Borrow, R, Martin, S, Robinson, M, Moxon, E, Pollard, A, Heath, P
Format: Journal article
Language:English
Published: Elsevier 2007
Subjects:
_version_ 1797053009181540352
author Ruggeberg, J
Collins, C
Clarke, P
Johnson, N
Sinha, R
Everest, N
Chang, J
Stanford, E
Balmer, P
Borrow, R
Martin, S
Robinson, M
Moxon, E
Pollard, A
Heath, P
author_facet Ruggeberg, J
Collins, C
Clarke, P
Johnson, N
Sinha, R
Everest, N
Chang, J
Stanford, E
Balmer, P
Borrow, R
Martin, S
Robinson, M
Moxon, E
Pollard, A
Heath, P
author_sort Ruggeberg, J
collection OXFORD
description Data on the immunogenicity and memory induction of pneumococcal conjugate vaccines in very preterm infants is limited. We vaccinated 69 full term and 68 preterm infants (median gestational age (GA) 30 weeks) with a 7-valent pneumococcal conjugate vaccine (PCV7) at 2/3/4 months of age, followed by a plain polysaccharide booster at 12 months of age. IgG-GMC (ELISA) was significantly lower in preterm infants to six vaccine serotypes (ST) at 2 months and 5 months of age, to five ST at 12 months of age and to three ST at 13 months of age. A significantly lower proportion of preterm infants achieved IgG levels ≥ 0.35μg/ml to ST 4, 6B and 9V at 5 months and to ST 4, 6B, 18C, 19F and 23F at 12 months of age. Fold rises following the polysaccharide booster were comparable to those of term infants. At least 93% of both cohorts achieved IgG ≥ 0.35 μg/ml to all STs following booster vaccination. Pneumococcal conjugate vaccine at an accelerated schedule of 2/3/4 months of age is likely to provide protection against pneumococcal disease for preterm infants. Antibody concentrations wane over the first year of life in both preterm and term infants and booster vaccination is therefore likely to be important.
first_indexed 2024-03-06T18:38:20Z
format Journal article
id oxford-uuid:0c0fc5d8-fc64-4f43-ab66-252fa85620cc
institution University of Oxford
language English
last_indexed 2024-03-06T18:38:20Z
publishDate 2007
publisher Elsevier
record_format dspace
spelling oxford-uuid:0c0fc5d8-fc64-4f43-ab66-252fa85620cc2022-03-26T09:32:47ZImmunogenicity and induction of immunological memory of the heptavalent pneumococcal conjugate vaccine in preterm UK infantsJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:0c0fc5d8-fc64-4f43-ab66-252fa85620ccPaediatricsInfectious diseasesVaccinologyEnglishOxford University Research Archive - ValetElsevier2007Ruggeberg, JCollins, CClarke, PJohnson, NSinha, REverest, NChang, JStanford, EBalmer, PBorrow, RMartin, SRobinson, MMoxon, EPollard, AHeath, PData on the immunogenicity and memory induction of pneumococcal conjugate vaccines in very preterm infants is limited. We vaccinated 69 full term and 68 preterm infants (median gestational age (GA) 30 weeks) with a 7-valent pneumococcal conjugate vaccine (PCV7) at 2/3/4 months of age, followed by a plain polysaccharide booster at 12 months of age. IgG-GMC (ELISA) was significantly lower in preterm infants to six vaccine serotypes (ST) at 2 months and 5 months of age, to five ST at 12 months of age and to three ST at 13 months of age. A significantly lower proportion of preterm infants achieved IgG levels ≥ 0.35μg/ml to ST 4, 6B and 9V at 5 months and to ST 4, 6B, 18C, 19F and 23F at 12 months of age. Fold rises following the polysaccharide booster were comparable to those of term infants. At least 93% of both cohorts achieved IgG ≥ 0.35 μg/ml to all STs following booster vaccination. Pneumococcal conjugate vaccine at an accelerated schedule of 2/3/4 months of age is likely to provide protection against pneumococcal disease for preterm infants. Antibody concentrations wane over the first year of life in both preterm and term infants and booster vaccination is therefore likely to be important.
spellingShingle Paediatrics
Infectious diseases
Vaccinology
Ruggeberg, J
Collins, C
Clarke, P
Johnson, N
Sinha, R
Everest, N
Chang, J
Stanford, E
Balmer, P
Borrow, R
Martin, S
Robinson, M
Moxon, E
Pollard, A
Heath, P
Immunogenicity and induction of immunological memory of the heptavalent pneumococcal conjugate vaccine in preterm UK infants
title Immunogenicity and induction of immunological memory of the heptavalent pneumococcal conjugate vaccine in preterm UK infants
title_full Immunogenicity and induction of immunological memory of the heptavalent pneumococcal conjugate vaccine in preterm UK infants
title_fullStr Immunogenicity and induction of immunological memory of the heptavalent pneumococcal conjugate vaccine in preterm UK infants
title_full_unstemmed Immunogenicity and induction of immunological memory of the heptavalent pneumococcal conjugate vaccine in preterm UK infants
title_short Immunogenicity and induction of immunological memory of the heptavalent pneumococcal conjugate vaccine in preterm UK infants
title_sort immunogenicity and induction of immunological memory of the heptavalent pneumococcal conjugate vaccine in preterm uk infants
topic Paediatrics
Infectious diseases
Vaccinology
work_keys_str_mv AT ruggebergj immunogenicityandinductionofimmunologicalmemoryoftheheptavalentpneumococcalconjugatevaccineinpretermukinfants
AT collinsc immunogenicityandinductionofimmunologicalmemoryoftheheptavalentpneumococcalconjugatevaccineinpretermukinfants
AT clarkep immunogenicityandinductionofimmunologicalmemoryoftheheptavalentpneumococcalconjugatevaccineinpretermukinfants
AT johnsonn immunogenicityandinductionofimmunologicalmemoryoftheheptavalentpneumococcalconjugatevaccineinpretermukinfants
AT sinhar immunogenicityandinductionofimmunologicalmemoryoftheheptavalentpneumococcalconjugatevaccineinpretermukinfants
AT everestn immunogenicityandinductionofimmunologicalmemoryoftheheptavalentpneumococcalconjugatevaccineinpretermukinfants
AT changj immunogenicityandinductionofimmunologicalmemoryoftheheptavalentpneumococcalconjugatevaccineinpretermukinfants
AT stanforde immunogenicityandinductionofimmunologicalmemoryoftheheptavalentpneumococcalconjugatevaccineinpretermukinfants
AT balmerp immunogenicityandinductionofimmunologicalmemoryoftheheptavalentpneumococcalconjugatevaccineinpretermukinfants
AT borrowr immunogenicityandinductionofimmunologicalmemoryoftheheptavalentpneumococcalconjugatevaccineinpretermukinfants
AT martins immunogenicityandinductionofimmunologicalmemoryoftheheptavalentpneumococcalconjugatevaccineinpretermukinfants
AT robinsonm immunogenicityandinductionofimmunologicalmemoryoftheheptavalentpneumococcalconjugatevaccineinpretermukinfants
AT moxone immunogenicityandinductionofimmunologicalmemoryoftheheptavalentpneumococcalconjugatevaccineinpretermukinfants
AT pollarda immunogenicityandinductionofimmunologicalmemoryoftheheptavalentpneumococcalconjugatevaccineinpretermukinfants
AT heathp immunogenicityandinductionofimmunologicalmemoryoftheheptavalentpneumococcalconjugatevaccineinpretermukinfants